Sutro Biopharma Inc (NASDAQ:STRO) shares, rose in value, with the stock price up by 1.47% to the previous day’s close as strong demand from buyers drove the stock to $1.38.
Actively observing the price movement in the recent trading, the stock is buoying the session at $1.36. Referring to stock’s 52-week performance, its high was $6.13, and the low was $1.34. On the whole, STRO has fluctuated by -30.65% over the past month.
With the market capitalization of Sutro Biopharma Inc currently standing at about $113.79 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 12.18M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that STRO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of STRO currently trading nearly -18.13% and -24.57% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 30.21, while the 7-day volatility ratio is showing 9.22% which for the 30-day chart, stands at 8.03%. Furthermore, Sutro Biopharma Inc (STRO)’s beta value is 1.48, and its average true range (ATR) is 0.13.
A comparison of Sutro Biopharma Inc (STRO) with its peers suggests the former has fared considerably weaker in the market. STRO showed an intraday change of 1.47% in today’s session so far, and over the past year, it shrunk by -71.19%%.
Data on historical trading for Sutro Biopharma Inc (NASDAQ:STRO) indicates that the trading volumes over the past 3 months, they’ve averaged 1.06 million. According to company’s latest data on outstanding shares, there are 82.40 million shares outstanding.
Nearly 9.52% of Sutro Biopharma Inc’s shares belong to company insiders and institutional investors own 68.90% of the company’s shares. The stock has fallen by -25.00% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the STRO stock heading into the next quarter.
